Fly News Breaks for February 14, 2020
Feb 14, 2020 | 07:36 EDT
Canaccord analyst Kyle Rose raised his price target on DexCom to $300 from $255 following excellent Q4 results. The analyst sees several future growth opportunities to support 2020 growth and beyond and remains bullish on the long-term product pipeline, growing market, and opportunity to deliver upside in 2020. Rose reiterated his Buy rating on DexCom shares.
News For DXCM From the Last 2 Days
There are no results for your query DXCM